Diabetes and alzheimer disease, two overlapping pathologies with the same background: Oxidative stress

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Rosales Corral, Sergio ^a   Tan, Dun Xian ^b   Manchester, Lucien ^b   Reiter, Russel J ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; OXIDATIVE STRESS; PATHOLOGY;

ALZHEIMER DISEASE; ALZHEIMER'S; ALZHEIMER'S DISEASE; INSULIN RESISTANCE; NEURODEGENERATIVE; NEURODEGENERATIVE DISORDERS; PATHOPHYSIOLOGICAL; TYPE II DIABETES;

NEURODEGENERATIVE DISEASES;

ANTIOXIDANT; CALCIUM; ENZYME; THIOREDOXIN; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ALZHEIMER DISEASE; DIABETES MELLITUS; ENZYME REGULATION; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; REVIEW; METABOLISM; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY;

ALZHEIMER DISEASE; CALCIUM; DIABETES MELLITUS, TYPE 2; GLUTATHIONE; HUMANS; INFLAMMATION; MITOCHONDRIA; NADP; OXIDATIVE STRESS; THIOREDOXINS;

EID: 84924565894     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/985845     Document Type: Review

References (272)

1. World Health Organization, "Diabetes, fact sheet no. 312," in WHO Media Centre, Fact Sheets, World Health Organization, Ed., vol. 2014, World Health Organization, 2014.
2. M. Prince, E. Albanese, M. Guerchet, and M. Prina, "Alzheimer's disease international world Alzheimer report 2014. Dementia and risk reduction," in Alzheimer's Disease International World Alzheimer, Alzheimer's Disease International, Ed., p. 104, Alzheimer's Disease International, London, UK, 2014.
3. C. C. Huang, C. M. Chung, H. B. Leu et al., "Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study," PLoS ONE, vol. 9, no. 1, Article ID e87095, 2014.
4. E. Steen, B. M. Terry, E. J. Rivera et al., "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?" Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 63-80, 2005.
5. H. Yang, X. Jin, C. W. K. Lam, and S. K. Yan, "Oxidative stress and diabetes mellitus," Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1773-1782, 2011.
6. N. Lester-Coll, E. J. Rivera, S. J. Soscia, K. Doiron, J. R. Wands, and S. M. de la Monte, "Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease," Journal of Alzheimer's Disease, vol. 9, no. 1, pp. 13-33, 2006.
7. A. Ceriello and E. Motz, "Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 816-823, 2004.
8. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, no. 6865, pp. 813-820, 2001.
9. D. W. Lam and D. LeRoith, "The worldwide diabetes epidemic," Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 2, pp. 93-96, 2012.
10. J. H. Kinoshita and C. Nishimura, "The involvement of aldose reductase in diabetic complications," Diabetes/Metabolism Reviews, vol. 4, no. 4, pp. 323-337, 1988.
11. J. I. Malone, S. Hanna, S. Saporta et al., "Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory," Pediatric Diabetes, vol. 9, no. 6, pp. 531-539, 2008.
12. S. Rosales-Corral, R. J. Reiter, D. X. Tan, G. G. Ortiz, and G. Lopez-Armas, "Functional aspects of redox control during neuroinflammation," Antioxidants and Redox Signaling, vol. 13, no. 2, pp. 193-247, 2010.
13. D. O. Cristalli, N. Arnal, F. A. Marra, M. J. T. de Alaniz, and C. A. Marra, "Peripheral markers in neurodegenerative patients and their first-degree relatives," Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 48-56, 2012.
14. A. McCaddon, P. Hudson, D. Hill et al., "Alzheimer's disease and total plasma aminothiols," Biological Psychiatry, vol. 53, no. 3, pp. 254-260, 2003.
15. S. Saharan and P. K. Mandai, "The emerging role of glutathione in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 40, pp. 519-529, 2014.
16. J. Unger, "Reducing oxidative stress in patients with type 2 diabetes mellitus: a primary care call to action," Insulin, vol. 3, no. 3, pp. 176-184, 2008.
17. G. de Luca, P. R. Calpona, A. Caponetti et al., "Amino acid profile in platelets of diabetic patients," Metabolism: Clinical and Experimental, vol. 50, no. 7, pp. 739-741, 2001.
18. R. V. Sekhar, S. V. Mckay, S. G Patel et al, "Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine," Diabetes Care, vol. 34, no. 1, pp. 162-167, 2011.
19. J. T. Greenamyre, W. F. Maragos, R. L. Albin, J. B. Penney, and A. B. Young, "Glutamate transmission and toxicity in Alzheimer's disease," Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 12, no. 4, pp. 421-IN4, 1988.
20. K. F. S. Bell, D. A. Bennett, and A. C. Cuello, "Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment," The Journal of Neuroscience, vol. 27, no. 40, pp. 10810-10817, 2007
21. S. A. Rosales-Corral, D. Acuna-Castroviejo, A. Coto-Montes et al., "Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin," Journal of Pineal Research, vol. 52, no. 2, pp. 167-202, 2012.
22. M. Domercq, M. V. Sanchez-Gomez, C. Sherwin, E. Etxebarria, R. Fern, and C. Matute, "System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes," The Journal of Immunology, vol. 178, no. 10, pp. 6549-6556, 2007.
23. P. Maher, R. Dargusch, J. L. Ehren, S. Okada, K. Sharma, and D. Schubert, "Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes," PLoS ONE, vol. 6, no. 6, Article ID e21226, 2011.
24. A. Rahigude, P. Bhutada, S. Kaulaskar, M. Aswar, and K. Otari, "Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats," Neuroscience, vol. 226, pp. 62-72, 2012.
25. V. Calabrese, C. Cornelius, V. Leso et al., "Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1822, no. 5, pp. 729-736, 2012.
26. M. C. Vantyghem, M. Balduyck, F. Zerimech et al., "Oxidative markers in diabetic ketoacidosis," Journal of Endocrinological Investigation, vol. 23, no. 11, pp. 732-736, 2000.
27. Y. Xu, B. W. Osborne, and R. C. Stanton, "Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex," The American Journal of Physiology-Renal Physiology, vol. 289, no. 5, pp. F1040-F1047, 2005.
28. G. A. Jicha, C. Weaver, E. Lane et al., "cAMP-dependent protein kinase phosphorylations on Tau in Alzheimer's disease," The Journal of Neuroscience, vol. 19, no. 17, pp. 7486-7494, 1999.
29. Q. Tian, J. X. Zhang, Y. Zhang et al., "Biphasic effects of forskolin on tau phosphorylation and spatial memory in rats," Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 631-642, 2009.
30. O. V. Vitolo, A. SantAngelo, V Costanzo, F. Battaglia, O. Arancio, and M. Shelanski, "Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 13217-13221, 2002.
31. I. S. Ovey and M. Naziroglu, "Homocysteine and cytosolic GSH depletion induce apoptosis and oxidative toxicity through cytosolic calcium overload in the hippocampus of aged mice: involvement of TRPM2 and TRPV1 channels," Neuroscience, vol. 284, pp. 225-233, 2015.
32. S. L. Chiu, C. M. Chen, and H. T. Cline, "Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo," Neuron, vol. 58, no. 5, pp. 708-719, 2008.
33. I. S. Kil, J. H. Lee, A. H. Shin, and J. W. Park, "Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: Implications for diabetes and aging," Free Radical Biology and Medicine, vol. 37, no. 11, pp. 1765-1778, 2004.
34. +-dependent isocitrate dehydrogenase," The Journal of Biological Chemistry, vol. 276, no. 19, pp. 16168-16176, 2001.
35. K. E Petersen, S. Dufour, D. Befroy, R. Garcia, and G. I. Shulman, "Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes," The New England Journal of Medicine, vol. 350, no. 7, pp. 664-671, 2004.
36. I. Giardino, D. Edelstein, and M. Brownlee, "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells," The Journal of Clinical Investigation, vol. 97, no. 6, pp. 1422-1428, 1996.
37. T. Nishikawa, D. Edelstein, X L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage," Nature, vol. 404, no. 6779, pp. 787-790, 2000.
38. W. H. Tang, K. A. Martin, and J. Hwa, "Aldose reductase, oxidative stress, and diabetic mellitus," Frontiers in Pharmacology, vol. 3, article 87, 2012.
39. R. Vogel, H. Wiesinger, and B. Hamprecht, "Postnatal development of malic enzyme isoforms in rat brain," in Neurochemistry, A. Teelken and J. Korf, Eds., pp. 765-769, Springer, Boston, MA, USA, 1997
40. W. O. Nagel, R. T. Dauchy, and L. A. Sauer, "Mitochondrial malic enzymes. An association between NAD(P)+-dependent malic enzyme and cell renewal in Sprague-Dawley rat tissues," The Journal of Biological Chemistry, vol. 255, no. 9, pp. 3849-3854, 1980.
41. G. M. Kurz, H. Wiesinger, and B. Hamprecht, "Purification of cytosolic malic enzyme from bovine brain, generation of monoclonal antibodies, and immunocytochemical localization of the enzyme in glial cells of neural primary cultures," Journal of Neurochemistry, vol. 60, no. 4, pp. 1467-1474, 1993.
42. R. Vogel, B. Hamprecht, and H. Wiesinger, "Malic enzyme isoforms in astrocytes: comparative study on activities in rat brain tissue and astroglia-rich primary cultures," Neuroscience Letters, vol. 247, no. 2-3, pp. 123-126, 1998.
43. F. Belfiore, A. M. Rabuazzo, E. Napoli, V. Borzi, and L. Lo Vecchio, "Enzymes of glucose metabolism and of the citrate cleavage pathway in adipose tissue of normal and diabetic subjects," Diabetes, vol. 24, no. 10, pp. 865-873, 1975.
44. A. Lippoldt, C. A. Padilla, H. Gerst et al., "Localization of thioredoxin in the rat brain and functional implications," The Journal of Neuroscience, vol. 15, no. 10, pp. 6747-6756, 1995.
45. S. S. Hardas, R. Sultana, A. M. Clark et al., "Oxidative modification of lipoic acid by HNE in alzheimer disease brain," Redox Biology, vol. 1, no. 1, pp. 80-85, 2013.
46. A. H. Minn, C. Hafele, and A. Shalev, "Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis," Endocrinology, vol. 146, no. 5, pp. 2397-2405, 2005.
47. J. Chen, G Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, "Thioredoxin-interacting protein. A critical link between glucose toxicity and β-cell apoptosis," Diabetes, vol. 57, no. 4, pp. 938-944, 2008.
48. G. S. Kim, J. E. Jung, P. Narasimhan, H. Sakata, and P. H. Chan, "Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice," Neurobiology of Disease, vol. 46, no. 2, pp. 440-449, 2012.
49. A. G Lerner, J. P. Upton, P. V. K. Praveen et al., "IREla induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress," Cell Metabolism, vol. 16, no. 2, pp. 250-264, 2012.
50. M. V. Li, B. Chang, M. Imamura, N. Poungvarin, and L. Chan, "Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module," Diabetes, vol. 55, no. 5, pp. 1179-1189, 2006.
51. F.-X Yu and Y Luo, "Tandem ChoRE and CCAAT motifs and associated factors regulate txnip expression in response to glucose or adenosine-containing molecules," PLoS ONE, vol. 4, no. 12, Article ID e8397, 2009.
52. T. Gouget, M. Djelloul, J. Boucraut et al., "TXNIP, the major player in insulin resistance, is early over-expressed in the brain of the 5XFAD Alzheimer's mice model and is induced by Aβ in vitro: emerging role of TXNIP and inflammation in Alzheimer's Disease progression," Alzheimer's & Dementia, vol. 7, no. 4, p. S684, 2011.
53. J. Dunys, E. Duplan, and F. Checler, "The transcription factor X-box binding protein-1 in neurodegenerative diseases," Molecular Neurodegeneration, vol. 9, no. 1, article 35, 2014.
54. S. M. Son, J. Byun, S.-E. Roh, S. J. Kim, and I. Mook-Jung, "Reduced IRE1 mediates apoptotic cell death by disrupting calcium homeostasis via the InsP3 receptor," Cell Death and Disease, vol. 5, no. 4, Article ID e1188, 2014.
55. L. Gasparini, G. K. Gouras, R. Wang et al., "Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intra-neuronal beta-amyloid and requires mitogen-activated protein kinase signaling," The journal of Neuroscience, vol. 21, no. 8, pp. 2561-2570, 2001.
56. M. T. Gentile, C. Vecchione, A. Maffei et al., "Mechanisms of soluble beta-amyloid impairment of endothelial function," The journal of Biological Chemistry, vol. 279, no. 46, pp. 48135-48142, 2004.
57. A. I. Placido, C. M. F. Pereira, A. I. Duarte et al, "The role of endoplasmic reticulum in amyloid precursor protein processing and trafficking: implications for Alzheimer's disease," Biochimica et Biophysica Acta, vol. 1842, no. 9, pp. 1444-1453, 2014.
58. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors," Nature Communications, vol. 3, article 2339, 2012.
59. S. Rosales-Corral, D. X Tan, R. J. Reiter, M. Valdivia-Velázquez, J. P. Acosta-Martínez, and G G. Ortiz, "Kinetics of the neuroin-flammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus in vivo," journal of Neuroimmunology, vol. 150, no. 1-2, pp. 20-28, 2004.
60. H. M. Wilkins, S. M. Carl, A. C. S. Greenlief, B. W. Festoff, and R. H. Swerdlow, "Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection," Frontiers in Aging Neuroscience, vol. 6, p. 311, 2014.
61. V. D. Dixit, "Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant?" Diabetes, vol. 62, no. 1, pp. 22-24, 2013.
62. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., "The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance," Nature Medicine, vol. 17, no. 2, pp. 179-189, 2011.
63. H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, "TLR4 links innate immunity and fatty acid-induced insulin resistance," The journal of Clinical Investigation, vol. 116, no. 11, pp. 3015-3025, 2006.
64. S. Mariathasan, D S. Weiss, K. Newton et al., "Cryopyrin activates the inflammasome in response to toxins and ATP," Nature, vol. 440, no. 7081, pp. 228-232, 2006.
65. A. Halle, V. Hornung, G C. Petzold et al., "The NALP3 inflammasome is involved in the innate immune response to amyloid-beta," Nature Immunology, vol. 9, no. 8, pp. 857-865, 2008.
66. 2+ waves trigger responses in microglial cells in brain slices," The FASEB journal, vol. 16, no. 2, pp. 255-257, 2002.
67. E Serrano, A. Chang, C. Hernandez, R. G Pautler, J. D. Sweatt, and E. Klann, "NADPH oxidase mediates beta-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures," Molecular Brain, vol. 2, no. 1, article 31, 2009.
68. M. L. Block, L. Zecca, and J.-S. Hong, "Microglia-mediated neurotoxicity: uncovering the molecular mechanisms," Nature Reviews Neuroscience, vol. 8, no. 1, pp. 57-69, 2007
69. A. M. Vincent, L. Perrone, K. A. Sullivan et al., "Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress," Endocrinology, vol. 148, no. 2, pp. 548-558, 2007
70. B. R. Choi, W. H. Cho, J. Kim et al., "Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease," Experimental and Molecular Medicine, vol. 46, article e75, 2014.
71. S. D. Yan, X. Chen, J. Fu et al, "RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease," Nature, vol. 382, no. 6593, pp. 685-691, 1996.
72. A. K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, and P. P. Nawroth, "The role of oxidative stress and NF-κB activation in late diabetic complications," BioFactors, vol. 10, no. 2-3, pp. 157-167, 1999.
73. A. M. Schmidt, O. Hori, J. Brett, S. D. Yan, J.-L. Wautier, and D. Stern, "Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, no. 10, pp. 1521-1528, 1994.
74. B. J. Goldstein, M. Kalyankar, and X Wu, "Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets," Diabetes, vol. 54, no. 2, pp. 311-321, 2005.
75. K. Mahadev, A. Zilbering, L. Zhu, and B. J. Goldstein, "Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase lb in vivo and enhances the early insulin action cascade," The journal of Biological Chemistry, vol. 276, no. 24, pp. 21938-21942, 2001.
76. H. Zhu, W. Gao, H. Jiang et al., "Regulation of acetylcholinesterase expression by calcium signaling during calcium ionophore A2," The International journal of Biochemistry & Cell Biology, vol. 39, pp. 93-108, 2007
77. E. S. Schweitzer, "Regulated and constitutive secretion of distinct molecular forms of acetylcholinesterase from PC12 cells," journal of Cell Science, vol. 106, no. 3, pp. 731-740, 1993.
78. G. Sberna, J. Sáez-Valero, K. Beyreuther, C. L. Masters, and D. H. Small, "The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells," journal of Neurochemistry, vol. 69, no. 3, pp. 1177-1184, 1997
79. M. P. Mattson, B. Cheng, D Davis, K. Bryant, I. Lieberburg, and R. E. Rydel, "beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity," The journal of Neuroscience, vol. 12, no. 2, pp. 376-389, 1992.
80. T. Day and S. A. Greenfield, "A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms," Neuroscience, vol. 111, no. 3, pp. 649-656, 2002.
81. 2+ mobilization and glutamate exocytosis in cerebral synap-tosomes from mice," Diabetes Research and Clinical Practice, vol. 81, no. 2, pp. el4-el7, 2008.
82. G. M. Keeling, Determination of the molecular mechanisms of hyperglycemia-induced changes in Cav3.2 calcium channel properties[M.S. thesis], Loyola University Chicago, Chicago, Ill, USA, 2012.
83. J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. J. Davis Parker, "Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro," Journal of Neurochemistry, vol. 76, no. 4, pp. 1050-1056, 2001.
84. L. I. Leichert, E Gehrke, H. V. Gudiseva et al., "Quantifying changes in the thiol redox proteome upon oxidative stress in vivo" Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8197-8202, 2008.
85. L. Frölich, D. Blum-Degen, H.-G Bernstein et al., "Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease," Journal of Neural Transmission, vol. 105, no. 4-5, pp. 423-438, 1998.
86. S. M. de la Monte, "Insulin resistance and Alzheimer's disease," BMB Reports, vol. 42, no. 8, pp. 475-481, 2009.
87. R. Agrawal, E. Tyagi, R. Shukla, and G Nath, "A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia," Neuropharmacology, vol. 56, no. 4, pp. 779-787, 2009.
88. W. Dröge, "Redox regulation in anabolic and catabolic processes," Current Opinion in Clinical Nutrition and Metabolic Care, vol. 9, no. 3, pp. 190-195, 2006.
89. 2 in tumor necrosis factor alpha-mediated insulin resistance," The Journal of Biological Chemistry, vol. 274, no. 35, pp. 25078-25084, 1999.
90. A. Tirosh, R. Potashnik, N. Bashan, and A. Rudich, "Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation," The Journal of Biological Chemistry, vol. 274, no. 15, pp. 10595-10602, 1999.
91. Z. Cheng, Y. Tseng, and M. E White, "Insulin signaling meets mitochondria in metabolism," Trends in Endocrinology and Metabolism, vol. 21, no. 10, pp. 589-598, 2010.
92. T. O. Johnson, J. Ermolieff, and M. R. Jirousek, "Protein tyrosine phosphatase 1B inhibitors for diabetes," Nature Reviews Drug Discovery, vol. 1, no. 9, pp. 696-709, 2002.
93. S. G. Rhee, T. S. Chang, Y S. Bae, S.-R. Lee, and S. W. Kang, "Cellular regulation by hydrogen peroxide," Journal of the American Society of Nephrology, vol. 14, no. 3, pp. S211-S215, 2003.
94. J. M. Denu and K. G. Tanner, "Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation," Biochemistry, vol. 37, no. 16, pp. 5633-5642, 1998.
95. G. Zhang, M. G. Kazanietz, P. M. Blumberg, and J. H. Hurley, "Crystal structure of the Cys2 activator-binding domain of protein kinase CΔ in complex with phorbol ester," Cell, vol. 81, no. 6, pp. 917-924, 1995.
96. I. Korichneva, "Redox regulation of cardiac protein kinase C," Experimental and Clinical Cardiology, vol. 10, no. 4, pp. 256-261, 2005.
97. Y Ono, T. Fujii, K. Igarashi et al., "Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 4868-4871, 1989.
98. C. Klomsiri, P. A. Karplus, and L. B. Poole, "Cysteine-based redox switches in enzymes," Antioxidants & Redox Signaling, vol. 14, no. 6, pp. 1065-1077, 2011.
99. S. Barbirz, U. Jakob, and M. O. Glocker, "Mass spectrometry unravels disulfide bond formation as the mechanism that activates a molecular chaperone," The Journal of Biological Chemistry, vol. 275, no. 25, pp. 18759-18766, 2000.
100. R. Gopalakrishna and S. Jaken, "Protein kinase C signaling and oxidative stress," Tree Radical Biology and Medicine, vol. 28, no. 9, pp. 1349-1361, 2000.
101. F. Chu, N. E. Ward, and G A. O'Brian, "Potent inactivation of representative members of each PKC isozyme subfamily and PKD via S-thiolation by the tumor-promotion/progression antagonist glutathione but not by its precursor cysteine," Carcinogenesis, vol. 22, no. 8, pp. 1221-1229, 2001.
102. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, "Regulation of vascular endothelial growth factor expression by advanced glycation end products," The Journal of Biological Chemistry, vol. 276, no. 47, pp. 43836-43841, 2001.
103. D. Lin and D. J. Takemoto, "Oxidative activation of protein kinase Cgamma through the C1 domain. Effects on gap junctions," Journal of Biological Chemistry, vol. 280, no. 14, pp. 13682-13693, 2005.
104. S. Hofmann and M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism," in Diabetes Mellitus: A Tundamental and Clinical Text, D. LeRoith, S. I. Taylor, and J. M. Olefsky, Eds., pp. 1441-14457, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2004.
105. C. J. Phiel, C. A. Wilson, V. M.-Y Lee, and P. S. Klein, "GSK-3α regulates production of Alzheimer's disease amyloid-β peptides," Nature, vol. 423, no. 6938, pp. 435-439, 2003.
106. G. Zhu, D. Wang, Y.-H. Lin, T. McMahon, E. H. Koo, and R. O. Messing, "Protein kinase C ε suppresses Aβ production and promotes activation of α-secretase," Biochemical and Biophysical Research Communications, vol. 285, no. 4, pp. 997-1006, 2001.
107. G. Benitez-King, M. E. Hernández, R. Tovar, and G. Ramirez, "Melatonin activates PKC-α but not PKC-ε in N1E-115 cells," Neurochemistry International, vol. 39, no. 2, pp. 95-102, 2001.
108. G. Benitez-King, L. Ortiz-López, and G. Jiménez-Rubio, "Melatonin precludes cytoskeletal collapse caused by hydrogen peroxide: participation of protein kinase C," Therapy, vol. 2, no. 5, pp. 767-778, 2005.
109. G. T. Corbett, A. Roy, and K. Pahan, "Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for alzheimer disease therapy," The Journal of Biological Chemistry, vol. 288, no. 12, pp. 8299-8312, 2013.
110. G.-G. Xu, Y.-Q. Deng, S.-J. Liu, H.-L. Li, and J.-Z. Wang, "Prolonged Alzheimer-like tau hyperphosphorylation induced by simultaneous inhibition of phosphoinositol-3 kinase and protein kinase C in N2a cells," Acta Biochimica et Biophysica Sinica, vol. 37, no. 5, pp. 349-354, 2005.
111. A. Chauhan, V. P. S. Chauhan, H. Brockerhoff, and H. M. Wisniewski, "Action of amyloid beta-protein on protein kinase C activity," Life Sciences, vol. 49, no. 21, pp. 1555-1562, 1991.
112. R. Etcheberrigaray, M. Tan, I. Dewachtert et al., "Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11141-11146, 2004.
113. C. Moran, T. G. Phan, J. Chen et al., "Brain atrophy in type 2 diabetes: regional distribution and influence on cognition," Diabetes Care, vol. 36, no. 12, pp. 4036-4042, 2013.
114. D. J. Loegering and M. R. Lennartz, "Protein kinase C and tolllike receptor signaling," Enzyme Research, vol. 2011, no. 1, Article ID 537821, 2011.
115. A. I. Duarte, P. Santos, C. R. Oliveira, M. S. Santos, and A. C. Rego, "Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1783, no. 6, pp. 994-1002, 2008.
116. J. B. Hoppe, R. L. Frozza, A. P. Horn et al., "Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation," Journal of Pineal Research, vol. 48, no. 3, pp. 230-238, 2010.
117. H. K. Lee, P. Kumar, Q. Fu, K. M. Rosen, and H. W. Querfurth, "The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid," Molecular Biology of the Cell, vol. 20, no. 5, pp. 1533-1544, 2009.
118. F. G. de Felice, M. N. N. Vieira, T. R. Bomfim et al., "Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 6, pp. 1971-1976, 2009.
119. A. M. Moloney, R. J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and G O'Neill, "Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling," Neurobiology of Aging, vol. 31, no. 2, pp. 224-243, 2010.
120. L. Ho, W. Qin, P. N. Pompl et al., "Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease," The FASEB Journal, vol. 18, no. 7, pp. 902-904, 2004.
121. W. Farris, S. Mansourian, Y. Chang et al., "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162-4167, 2003.
122. I. V. Kurochkin and S. Goto, "Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme," FEBS Letters, vol. 345, no. 1, pp. 33-37, 1994.
123. M. Neant-Fery, R. D. Garcia-Ordonez, T. P. Logan et al., "Molecular basis for the thiol sensitivity of insulin-degrading enzyme," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9582-9587, 2008.
124. C. M. Cordes, R. G. Bennett, G. L. Siford, and F. G. Hamel, "Redox regulation of insulin degradation by insulin-degrading enzyme," PLoS ONE, vol. 6, no. 3, Article ID el8138, 2011.
125. H. Shinall, E. S. Song, and L. B. Hersh, "Susceptibility of amyloid β peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral," Biochemistry, vol. 44, no. 46, pp. 15345-15350, 2005.
126. K. Runyan, W. C. Duckworth, A. E. Kitabchi, and G. Huff, "The effect of age on insulin-degrading activity in rat tissue," Diabetes, vol. 28, no. 4, pp. 324-325, 1979.
127. F. G. Hamel, J. L. Upward, and R. G. Bennett, "In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters," Endocrinology, vol. 144, no. 6, pp. 2404-2408, 2003.
128. H. Gutiérrez-Hermosillo, D. de León-Gonzáleze, R. Palacios-Corona et al., "C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study," Medicina Clinica, vol. 144, no. 4, pp. 151-155, 2015.
129. X. Du, T. Matsumura, D. Edelstein et al., "Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells," The Journal of Clinical Investigation, vol. 112, no. 7, pp. 1049-1057, 2003.
130. A. Colell, D. R. Green, and J.-E. Ricci, "Novel roles for GAPDH in cell death and carcinogenesis," Cell Death and Differentiation, vol. 16, no. 12, pp. 1573-1581, 2009.
131. L. L. Kusner, V. P. Sarthy, and S. Mohr, "Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells," Investigative Ophthalmology and Visual Science, vol. 45, no. 5, pp. 1553-1561, 2004.
132. M. R. Hara, M. B. Cascio, and A. Sawa, "GAPDH as a sensor of NO stress," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1762, no. 5, pp. 502-509, 2006.
133. D. A. Butterfield, S. S. Hardas, and M. L. B. Lange, "Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alzheimer's disease: many pathways to neurode-generation," Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 369-393, 2010.
134. S. F. Newman, R. Sultana, M. Perluigi et al., "An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach," Journal of Neuroscience Research, vol. 85, no. 7, pp. 1506-1514, 2007
135. I. Ferrer, T. Gomez-Isla, B. Puig et al., "Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies," Current Alzheimer Research, vol. 2, no. 1, pp. 3-18, 2005.
136. E. F. Pettersen, T. D. Goddard, C. C. Huang et al., "UCSF Chimera - a visualization system for exploratory research and analysis," Journal of Computational Chemistry, vol. 25, no. 13, pp. 1605-1612, 2004.
137. World Health Organization, "Diabetes, fact sheet no. 312," in WHO Media Centre, Fact Sheets, World Health Organization, Ed., vol. 2014, World Health Organization, 2014.
138. M. Prince, E. Albanese, M. Guerchet, and M. Prina, "Alzheimer's disease international world Alzheimer report 2014. Dementia and risk reduction," in Alzheimer's Disease International World Alzheimer, Alzheimer's Disease International, Ed., p. 104, Alzheimer's Disease International, London, UK, 2014.
139. C. C. Huang, C. M. Chung, H. B. Leu et al., "Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study," PLoS ONE, vol. 9, no. 1, Article ID e87095, 2014.
140. E. Steen, B. M. Terry, E. J. Rivera et al., "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?" Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 63-80, 2005.
141. H. Yang, X. Jin, C. W. K. Lam, and S. K. Yan, "Oxidative stress and diabetes mellitus," Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1773-1782, 2011.
142. N. Lester-Coll, E. J. Rivera, S. J. Soscia, K. Doiron, J. R. Wands, and S. M. de la Monte, "Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease," Journal of Alzheimer's Disease, vol. 9, no. 1, pp. 13-33, 2006.
143. A. Ceriello and E. Motz, "Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 816-823, 2004.
144. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, no. 6865, pp. 813-820, 2001.
145. D. W. Lam and D. LeRoith, "The worldwide diabetes epidemic," Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 2, pp. 93-96, 2012.
146. J. H. Kinoshita and C. Nishimura, "The involvement of aldose reductase in diabetic complications," Diabetes/Metabolism Reviews, vol. 4, no. 4, pp. 323-337, 1988.
147. J. I. Malone, S. Hanna, S. Saporta et al., "Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory," Pediatric Diabetes, vol. 9, no. 6, pp. 531-539, 2008.
148. S. Rosales-Corral, R. J. Reiter, D. X. Tan, G. G. Ortiz, and G. Lopez-Armas, "Functional aspects of redox control during neuroinflammation," Antioxidants and Redox Signaling, vol. 13, no. 2, pp. 193-247, 2010.
149. D. O. Cristalli, N. Arnal, F. A. Marra, M. J. T. de Alaniz, and C. A. Marra, "Peripheral markers in neurodegenerative patients and their first-degree relatives," Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 48-56, 2012.
150. A. McCaddon, P. Hudson, D. Hill et al., "Alzheimer's disease and total plasma aminothiols," Biological Psychiatry, vol. 53, no. 3, pp. 254-260, 2003.
151. S. Saharan and P. K. Mandai, "The emerging role of glutathione in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 40, pp. 519-529, 2014.
152. J. Unger, "Reducing oxidative stress in patients with type 2 diabetes mellitus: a primary care call to action," Insulin, vol. 3, no. 3, pp. 176-184, 2008.
153. G. de Luca, P. R. Calpona, A. Caponetti et al., "Amino acid profile in platelets of diabetic patients," Metabolism: Clinical and Experimental, vol. 50, no. 7, pp. 739-741, 2001.
154. R. V. Sekhar, S. V. Mckay, S. G Patel et al, "Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine," Diabetes Care, vol. 34, no. 1, pp. 162-167, 2011.
155. J. T. Greenamyre, W. F. Maragos, R. L. Albin, J. B. Penney, and A. B. Young, "Glutamate transmission and toxicity in Alzheimer's disease," Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 12, no. 4, pp. 421-IN4, 1988.
156. K. F. S. Bell, D. A. Bennett, and A. C. Cuello, "Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment," The Journal of Neuroscience, vol. 27, no. 40, pp. 10810-10817, 2007
157. S. A. Rosales-Corral, D. Acuna-Castroviejo, A. Coto-Montes et al., "Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin," Journal of Pineal Research, vol. 52, no. 2, pp. 167-202, 2012.
158. M. Domercq, M. V. Sanchez-Gomez, C. Sherwin, E. Etxebarria, R. Fern, and C. Matute, "System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes," The Journal of Immunology, vol. 178, no. 10, pp. 6549-6556, 2007.
159. P. Maher, R. Dargusch, J. L. Ehren, S. Okada, K. Sharma, and D. Schubert, "Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes," PLoS ONE, vol. 6, no. 6, Article ID e21226, 2011.
160. A. Rahigude, P. Bhutada, S. Kaulaskar, M. Aswar, and K. Otari, "Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats," Neuroscience, vol. 226, pp. 62-72, 2012.
161. V. Calabrese, C. Cornelius, V. Leso et al., "Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1822, no. 5, pp. 729-736, 2012.
162. M. C. Vantyghem, M. Balduyck, F. Zerimech et al., "Oxidative markers in diabetic ketoacidosis," Journal of Endocrinological Investigation, vol. 23, no. 11, pp. 732-736, 2000.
163. Y. Xu, B. W. Osborne, and R. C. Stanton, "Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex," The American Journal of Physiology-Renal Physiology, vol. 289, no. 5, pp. F1040-F1047, 2005.
164. G. A. Jicha, C. Weaver, E. Lane et al., "cAMP-dependent protein kinase phosphorylations on Tau in Alzheimer's disease," The Journal of Neuroscience, vol. 19, no. 17, pp. 7486-7494, 1999.
165. Q. Tian, J. X. Zhang, Y. Zhang et al., "Biphasic effects of forskolin on tau phosphorylation and spatial memory in rats," Journal of Alzheimer's Disease, vol. 17, no. 3, pp. 631-642, 2009.
166. O. V. Vitolo, A. SantAngelo, V Costanzo, F. Battaglia, O. Arancio, and M. Shelanski, "Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 13217-13221, 2002.
167. I. S. Ovey and M. Naziroglu, "Homocysteine and cytosolic GSH depletion induce apoptosis and oxidative toxicity through cytosolic calcium overload in the hippocampus of aged mice: involvement of TRPM2 and TRPV1 channels," Neuroscience, vol. 284, pp. 225-233, 2015.
168. S. L. Chiu, C. M. Chen, and H. T. Cline, "Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo," Neuron, vol. 58, no. 5, pp. 708-719, 2008.
169. I. S. Kil, J. H. Lee, A. H. Shin, and J. W. Park, "Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: Implications for diabetes and aging," Free Radical Biology and Medicine, vol. 37, no. 11, pp. 1765-1778, 2004.
170. +-dependent isocitrate dehydrogenase," The Journal of Biological Chemistry, vol. 276, no. 19, pp. 16168-16176, 2001.
171. K. E Petersen, S. Dufour, D. Befroy, R. Garcia, and G. I. Shulman, "Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes," The New England Journal of Medicine, vol. 350, no. 7, pp. 664-671, 2004.
172. I. Giardino, D. Edelstein, and M. Brownlee, "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells," The Journal of Clinical Investigation, vol. 97, no. 6, pp. 1422-1428, 1996.
173. T. Nishikawa, D. Edelstein, X L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage," Nature, vol. 404, no. 6779, pp. 787-790, 2000.
174. W. H. Tang, K. A. Martin, and J. Hwa, "Aldose reductase, oxidative stress, and diabetic mellitus," Frontiers in Pharmacology, vol. 3, article 87, 2012.
175. R. Vogel, H. Wiesinger, and B. Hamprecht, "Postnatal development of malic enzyme isoforms in rat brain," in Neurochemistry, A. Teelken and J. Korf, Eds., pp. 765-769, Springer, Boston, MA, USA, 1997
176. W. O. Nagel, R. T. Dauchy, and L. A. Sauer, "Mitochondrial malic enzymes. An association between NAD(P)+-dependent malic enzyme and cell renewal in Sprague-Dawley rat tissues," The Journal of Biological Chemistry, vol. 255, no. 9, pp. 3849-3854, 1980.
177. G. M. Kurz, H. Wiesinger, and B. Hamprecht, "Purification of cytosolic malic enzyme from bovine brain, generation of monoclonal antibodies, and immunocytochemical localization of the enzyme in glial cells of neural primary cultures," Journal of Neurochemistry, vol. 60, no. 4, pp. 1467-1474, 1993.
178. R. Vogel, B. Hamprecht, and H. Wiesinger, "Malic enzyme isoforms in astrocytes: comparative study on activities in rat brain tissue and astroglia-rich primary cultures," Neuroscience Letters, vol. 247, no. 2-3, pp. 123-126, 1998.
179. F. Belfiore, A. M. Rabuazzo, E. Napoli, V. Borzi, and L. Lo Vecchio, "Enzymes of glucose metabolism and of the citrate cleavage pathway in adipose tissue of normal and diabetic subjects," Diabetes, vol. 24, no. 10, pp. 865-873, 1975.
180. A. Lippoldt, C. A. Padilla, H. Gerst et al., "Localization of thioredoxin in the rat brain and functional implications," The Journal of Neuroscience, vol. 15, no. 10, pp. 6747-6756, 1995.
181. S. S. Hardas, R. Sultana, A. M. Clark et al., "Oxidative modification of lipoic acid by HNE in alzheimer disease brain," Redox Biology, vol. 1, no. 1, pp. 80-85, 2013.
182. A. H. Minn, C. Hafele, and A. Shalev, "Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis," Endocrinology, vol. 146, no. 5, pp. 2397-2405, 2005.
183. J. Chen, G Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, "Thioredoxin-interacting protein. A critical link between glucose toxicity and β-cell apoptosis," Diabetes, vol. 57, no. 4, pp. 938-944, 2008.
184. G. S. Kim, J. E. Jung, P. Narasimhan, H. Sakata, and P. H. Chan, "Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice," Neurobiology of Disease, vol. 46, no. 2, pp. 440-449, 2012.
185. A. G Lerner, J. P. Upton, P. V. K. Praveen et al., "IREla induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress," Cell Metabolism, vol. 16, no. 2, pp. 250-264, 2012.
186. M. V. Li, B. Chang, M. Imamura, N. Poungvarin, and L. Chan, "Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module," Diabetes, vol. 55, no. 5, pp. 1179-1189, 2006.
187. F.-X Yu and Y Luo, "Tandem ChoRE and CCAAT motifs and associated factors regulate txnip expression in response to glucose or adenosine-containing molecules," PLoS ONE, vol. 4, no. 12, Article ID e8397, 2009.
188. T. Gouget, M. Djelloul, J. Boucraut et al., "TXNIP, the major player in insulin resistance, is early over-expressed in the brain of the 5XFAD Alzheimer's mice model and is induced by Aβ in vitro: emerging role of TXNIP and inflammation in Alzheimer's Disease progression," Alzheimer's & Dementia, vol. 7, no. 4, p. S684, 2011.
189. J. Dunys, E. Duplan, and F. Checler, "The transcription factor X-box binding protein-1 in neurodegenerative diseases," Molecular Neurodegeneration, vol. 9, no. 1, article 35, 2014.
190. S. M. Son, J. Byun, S.-E. Roh, S. J. Kim, and I. Mook-Jung, "Reduced IRE1 mediates apoptotic cell death by disrupting calcium homeostasis via the InsP3 receptor," Cell Death and Disease, vol. 5, no. 4, Article ID e1188, 2014.
191. L. Gasparini, G. K. Gouras, R. Wang et al., "Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intra-neuronal beta-amyloid and requires mitogen-activated protein kinase signaling," The journal of Neuroscience, vol. 21, no. 8, pp. 2561-2570, 2001.
192. M. T. Gentile, C. Vecchione, A. Maffei et al., "Mechanisms of soluble beta-amyloid impairment of endothelial function," The journal of Biological Chemistry, vol. 279, no. 46, pp. 48135-48142, 2004.
193. A. I. Placido, C. M. F. Pereira, A. I. Duarte et al, "The role of endoplasmic reticulum in amyloid precursor protein processing and trafficking: implications for Alzheimer's disease," Biochimica et Biophysica Acta, vol. 1842, no. 9, pp. 1444-1453, 2014.
194. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors," Nature Communications, vol. 3, article 2339, 2012.
195. S. Rosales-Corral, D. X Tan, R. J. Reiter, M. Valdivia-Velázquez, J. P. Acosta-Martínez, and G G. Ortiz, "Kinetics of the neuroin-flammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus in vivo," journal of Neuroimmunology, vol. 150, no. 1-2, pp. 20-28, 2004.
196. H. M. Wilkins, S. M. Carl, A. C. S. Greenlief, B. W. Festoff, and R. H. Swerdlow, "Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection," Frontiers in Aging Neuroscience, vol. 6, p. 311, 2014.
197. V. D. Dixit, "Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant?" Diabetes, vol. 62, no. 1, pp. 22-24, 2013.
198. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., "The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance," Nature Medicine, vol. 17, no. 2, pp. 179-189, 2011.
199. H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, "TLR4 links innate immunity and fatty acid-induced insulin resistance," The journal of Clinical Investigation, vol. 116, no. 11, pp. 3015-3025, 2006.
200. S. Mariathasan, D S. Weiss, K. Newton et al., "Cryopyrin activates the inflammasome in response to toxins and ATP," Nature, vol. 440, no. 7081, pp. 228-232, 2006.
201. A. Halle, V. Hornung, G C. Petzold et al., "The NALP3 inflammasome is involved in the innate immune response to amyloid-beta," Nature Immunology, vol. 9, no. 8, pp. 857-865, 2008.
202. 2+ waves trigger responses in microglial cells in brain slices," The FASEB journal, vol. 16, no. 2, pp. 255-257, 2002.
203. E Serrano, A. Chang, C. Hernandez, R. G Pautler, J. D. Sweatt, and E. Klann, "NADPH oxidase mediates beta-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures," Molecular Brain, vol. 2, no. 1, article 31, 2009.
204. M. L. Block, L. Zecca, and J.-S. Hong, "Microglia-mediated neurotoxicity: uncovering the molecular mechanisms," Nature Reviews Neuroscience, vol. 8, no. 1, pp. 57-69, 2007
205. A. M. Vincent, L. Perrone, K. A. Sullivan et al., "Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress," Endocrinology, vol. 148, no. 2, pp. 548-558, 2007
206. B. R. Choi, W. H. Cho, J. Kim et al., "Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease," Experimental and Molecular Medicine, vol. 46, article e75, 2014.
207. S. D. Yan, X. Chen, J. Fu et al, "RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease," Nature, vol. 382, no. 6593, pp. 685-691, 1996.
208. A. K. Mohamed, A. Bierhaus, S. Schiekofer, H. Tritschler, R. Ziegler, and P. P. Nawroth, "The role of oxidative stress and NF-κB activation in late diabetic complications," BioFactors, vol. 10, no. 2-3, pp. 157-167, 1999.
209. A. M. Schmidt, O. Hori, J. Brett, S. D. Yan, J.-L. Wautier, and D. Stern, "Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, no. 10, pp. 1521-1528, 1994.
210. B. J. Goldstein, M. Kalyankar, and X Wu, "Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets," Diabetes, vol. 54, no. 2, pp. 311-321, 2005.
211. K. Mahadev, A. Zilbering, L. Zhu, and B. J. Goldstein, "Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase lb in vivo and enhances the early insulin action cascade," The journal of Biological Chemistry, vol. 276, no. 24, pp. 21938-21942, 2001.
212. H. Zhu, W. Gao, H. Jiang et al., "Regulation of acetylcholinesterase expression by calcium signaling during calcium ionophore A2," The International journal of Biochemistry & Cell Biology, vol. 39, pp. 93-108, 2007
213. E. S. Schweitzer, "Regulated and constitutive secretion of distinct molecular forms of acetylcholinesterase from PC12 cells," journal of Cell Science, vol. 106, no. 3, pp. 731-740, 1993.
214. G. Sberna, J. Sáez-Valero, K. Beyreuther, C. L. Masters, and D. H. Small, "The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells," journal of Neurochemistry, vol. 69, no. 3, pp. 1177-1184, 1997
215. M. P. Mattson, B. Cheng, D Davis, K. Bryant, I. Lieberburg, and R. E. Rydel, "beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity," The journal of Neuroscience, vol. 12, no. 2, pp. 376-389, 1992.
216. T. Day and S. A. Greenfield, "A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms," Neuroscience, vol. 111, no. 3, pp. 649-656, 2002.
217. 2+ mobilization and glutamate exocytosis in cerebral synap-tosomes from mice," Diabetes Research and Clinical Practice, vol. 81, no. 2, pp. el4-el7, 2008.
218. G. M. Keeling, Determination of the molecular mechanisms of hyperglycemia-induced changes in Cav3.2 calcium channel properties[M.S. thesis], Loyola University Chicago, Chicago, Ill, USA, 2012.
219. J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. J. Davis Parker, "Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro," Journal of Neurochemistry, vol. 76, no. 4, pp. 1050-1056, 2001.
220. L. I. Leichert, E Gehrke, H. V. Gudiseva et al., "Quantifying changes in the thiol redox proteome upon oxidative stress in vivo" Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8197-8202, 2008.
221. L. Frölich, D. Blum-Degen, H.-G Bernstein et al., "Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease," Journal of Neural Transmission, vol. 105, no. 4-5, pp. 423-438, 1998.
222. S. M. de la Monte, "Insulin resistance and Alzheimer's disease," BMB Reports, vol. 42, no. 8, pp. 475-481, 2009.
223. R. Agrawal, E. Tyagi, R. Shukla, and G Nath, "A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia," Neuropharmacology, vol. 56, no. 4, pp. 779-787, 2009.
224. W. Dröge, "Redox regulation in anabolic and catabolic processes," Current Opinion in Clinical Nutrition and Metabolic Care, vol. 9, no. 3, pp. 190-195, 2006.
225. 2 in tumor necrosis factor alpha-mediated insulin resistance," The Journal of Biological Chemistry, vol. 274, no. 35, pp. 25078-25084, 1999.
226. A. Tirosh, R. Potashnik, N. Bashan, and A. Rudich, "Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation," The Journal of Biological Chemistry, vol. 274, no. 15, pp. 10595-10602, 1999.
227. Z. Cheng, Y. Tseng, and M. E White, "Insulin signaling meets mitochondria in metabolism," Trends in Endocrinology and Metabolism, vol. 21, no. 10, pp. 589-598, 2010.
228. T. O. Johnson, J. Ermolieff, and M. R. Jirousek, "Protein tyrosine phosphatase 1B inhibitors for diabetes," Nature Reviews Drug Discovery, vol. 1, no. 9, pp. 696-709, 2002.
229. S. G. Rhee, T. S. Chang, Y S. Bae, S.-R. Lee, and S. W. Kang, "Cellular regulation by hydrogen peroxide," Journal of the American Society of Nephrology, vol. 14, no. 3, pp. S211-S215, 2003.
230. J. M. Denu and K. G. Tanner, "Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation," Biochemistry, vol. 37, no. 16, pp. 5633-5642, 1998.
231. G. Zhang, M. G. Kazanietz, P. M. Blumberg, and J. H. Hurley, "Crystal structure of the Cys2 activator-binding domain of protein kinase CΔ in complex with phorbol ester," Cell, vol. 81, no. 6, pp. 917-924, 1995.
232. I. Korichneva, "Redox regulation of cardiac protein kinase C," Experimental and Clinical Cardiology, vol. 10, no. 4, pp. 256-261, 2005.
233. Y Ono, T. Fujii, K. Igarashi et al., "Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence," Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 4868-4871, 1989.
234. C. Klomsiri, P. A. Karplus, and L. B. Poole, "Cysteine-based redox switches in enzymes," Antioxidants & Redox Signaling, vol. 14, no. 6, pp. 1065-1077, 2011.
235. S. Barbirz, U. Jakob, and M. O. Glocker, "Mass spectrometry unravels disulfide bond formation as the mechanism that activates a molecular chaperone," The Journal of Biological Chemistry, vol. 275, no. 25, pp. 18759-18766, 2000.
236. R. Gopalakrishna and S. Jaken, "Protein kinase C signaling and oxidative stress," Tree Radical Biology and Medicine, vol. 28, no. 9, pp. 1349-1361, 2000.
237. F. Chu, N. E. Ward, and G A. O'Brian, "Potent inactivation of representative members of each PKC isozyme subfamily and PKD via S-thiolation by the tumor-promotion/progression antagonist glutathione but not by its precursor cysteine," Carcinogenesis, vol. 22, no. 8, pp. 1221-1229, 2001.
238. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, "Regulation of vascular endothelial growth factor expression by advanced glycation end products," The Journal of Biological Chemistry, vol. 276, no. 47, pp. 43836-43841, 2001.
239. D. Lin and D. J. Takemoto, "Oxidative activation of protein kinase Cgamma through the C1 domain. Effects on gap junctions," Journal of Biological Chemistry, vol. 280, no. 14, pp. 13682-13693, 2005.
240. S. Hofmann and M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism," in Diabetes Mellitus: A Tundamental and Clinical Text, D. LeRoith, S. I. Taylor, and J. M. Olefsky, Eds., pp. 1441-14457, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2004.
241. C. J. Phiel, C. A. Wilson, V. M.-Y Lee, and P. S. Klein, "GSK-3α regulates production of Alzheimer's disease amyloid-β peptides," Nature, vol. 423, no. 6938, pp. 435-439, 2003.
242. G. Zhu, D. Wang, Y.-H. Lin, T. McMahon, E. H. Koo, and R. O. Messing, "Protein kinase C ε suppresses Aβ production and promotes activation of α-secretase," Biochemical and Biophysical Research Communications, vol. 285, no. 4, pp. 997-1006, 2001.
243. G. Benitez-King, M. E. Hernández, R. Tovar, and G. Ramirez, "Melatonin activates PKC-α but not PKC-ε in N1E-115 cells," Neurochemistry International, vol. 39, no. 2, pp. 95-102, 2001.
244. G. Benitez-King, L. Ortiz-López, and G. Jiménez-Rubio, "Melatonin precludes cytoskeletal collapse caused by hydrogen peroxide: participation of protein kinase C," Therapy, vol. 2, no. 5, pp. 767-778, 2005.
245. G. T. Corbett, A. Roy, and K. Pahan, "Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for alzheimer disease therapy," The Journal of Biological Chemistry, vol. 288, no. 12, pp. 8299-8312, 2013.
246. G.-G. Xu, Y.-Q. Deng, S.-J. Liu, H.-L. Li, and J.-Z. Wang, "Prolonged Alzheimer-like tau hyperphosphorylation induced by simultaneous inhibition of phosphoinositol-3 kinase and protein kinase C in N2a cells," Acta Biochimica et Biophysica Sinica, vol. 37, no. 5, pp. 349-354, 2005.
247. A. Chauhan, V. P. S. Chauhan, H. Brockerhoff, and H. M. Wisniewski, "Action of amyloid beta-protein on protein kinase C activity," Life Sciences, vol. 49, no. 21, pp. 1555-1562, 1991.
248. R. Etcheberrigaray, M. Tan, I. Dewachtert et al., "Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11141-11146, 2004.
249. C. Moran, T. G. Phan, J. Chen et al., "Brain atrophy in type 2 diabetes: regional distribution and influence on cognition," Diabetes Care, vol. 36, no. 12, pp. 4036-4042, 2013.
250. D. J. Loegering and M. R. Lennartz, "Protein kinase C and tolllike receptor signaling," Enzyme Research, vol. 2011, no. 1, Article ID 537821, 2011.
251. A. I. Duarte, P. Santos, C. R. Oliveira, M. S. Santos, and A. C. Rego, "Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1783, no. 6, pp. 994-1002, 2008.
252. J. B. Hoppe, R. L. Frozza, A. P. Horn et al., "Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation," Journal of Pineal Research, vol. 48, no. 3, pp. 230-238, 2010.
253. H. K. Lee, P. Kumar, Q. Fu, K. M. Rosen, and H. W. Querfurth, "The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid," Molecular Biology of the Cell, vol. 20, no. 5, pp. 1533-1544, 2009.
254. F. G. de Felice, M. N. N. Vieira, T. R. Bomfim et al., "Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 6, pp. 1971-1976, 2009.
255. A. M. Moloney, R. J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and G O'Neill, "Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling," Neurobiology of Aging, vol. 31, no. 2, pp. 224-243, 2010.
256. L. Ho, W. Qin, P. N. Pompl et al., "Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease," The FASEB Journal, vol. 18, no. 7, pp. 902-904, 2004.
257. W. Farris, S. Mansourian, Y. Chang et al., "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162-4167, 2003.
258. I. V. Kurochkin and S. Goto, "Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme," FEBS Letters, vol. 345, no. 1, pp. 33-37, 1994.
259. M. Neant-Fery, R. D. Garcia-Ordonez, T. P. Logan et al., "Molecular basis for the thiol sensitivity of insulin-degrading enzyme," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9582-9587, 2008.
260. C. M. Cordes, R. G. Bennett, G. L. Siford, and F. G. Hamel, "Redox regulation of insulin degradation by insulin-degrading enzyme," PLoS ONE, vol. 6, no. 3, Article ID el8138, 2011.
261. H. Shinall, E. S. Song, and L. B. Hersh, "Susceptibility of amyloid β peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral," Biochemistry, vol. 44, no. 46, pp. 15345-15350, 2005.
262. K. Runyan, W. C. Duckworth, A. E. Kitabchi, and G. Huff, "The effect of age on insulin-degrading activity in rat tissue," Diabetes, vol. 28, no. 4, pp. 324-325, 1979.
263. F. G. Hamel, J. L. Upward, and R. G. Bennett, "In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters," Endocrinology, vol. 144, no. 6, pp. 2404-2408, 2003.
264. H. Gutiérrez-Hermosillo, D. de León-Gonzáleze, R. Palacios-Corona et al., "C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study," Medicina Clinica, vol. 144, no. 4, pp. 151-155, 2015.
265. X. Du, T. Matsumura, D. Edelstein et al., "Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells," The Journal of Clinical Investigation, vol. 112, no. 7, pp. 1049-1057, 2003.
266. A. Colell, D. R. Green, and J.-E. Ricci, "Novel roles for GAPDH in cell death and carcinogenesis," Cell Death and Differentiation, vol. 16, no. 12, pp. 1573-1581, 2009.
267. L. L. Kusner, V. P. Sarthy, and S. Mohr, "Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells," Investigative Ophthalmology and Visual Science, vol. 45, no. 5, pp. 1553-1561, 2004.
268. M. R. Hara, M. B. Cascio, and A. Sawa, "GAPDH as a sensor of NO stress," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1762, no. 5, pp. 502-509, 2006.
269. D. A. Butterfield, S. S. Hardas, and M. L. B. Lange, "Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alzheimer's disease: many pathways to neurode-generation," Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 369-393, 2010.
270. S. F. Newman, R. Sultana, M. Perluigi et al., "An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach," Journal of Neuroscience Research, vol. 85, no. 7, pp. 1506-1514, 2007
271. I. Ferrer, T. Gomez-Isla, B. Puig et al., "Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies," Current Alzheimer Research, vol. 2, no. 1, pp. 3-18, 2005.
272. E. F. Pettersen, T. D. Goddard, C. C. Huang et al., "UCSF Chimera - a visualization system for exploratory research and analysis," Journal of Computational Chemistry, vol. 25, no. 13, pp. 1605-1612, 2004.